| PDT | photodynamic therapy |
| ROS | reactive oxygen species |
| CSC | cancer stem cell |
| FDA | Food and Drug Administration |
| Ce6 | chlorin e6 |
| PTT | photothermal therapy |
| DAMP | damage-associated molecular pattern |
| COF | composite-type optical fiberscope |
| CELC | central early stage lung cancer |
| AuNP | gold nanoparticle |
| Ab | antibody |
| VEGF | vascular endothelial growth factor |
| HPPH | 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a |
| CIS | carcinomas in situ |
| MIC | microinvasive cancer |
| SCC | squamous cell carcinoma |
| mTHPC | m-tetrahydroxyphenylchlorin |
| EMA | European Medicines Agency |
| HPR | N-(4-hydroxyphenyl) retinamide |
| QOL | quality of life |
| EGFR | epidermal growth factor receptor |
| TPCS2a | disulfonated tetraphenyl chlorine |
| BCC | basal-cell carcinoma |
| 5-ALA | 5-aminolevulinic acid |
| AK | actinic keratosis |
| MAL | methyl aminolevulinate |
| EGCG | epigallocatechin gallate |
| MHRF | Ministry of Health of the Russian Federation |
| PpIX | protoporphyrin IX |
| ABCG2 | ATP-binding cassette transporter subfamily G2 |
| PSA | prostate-specific antigen |
| VTP | vascular-targeted PDT |
| SOF | supramolecular organic framework |
| MHLW | Ministry of Health, Labor and Welfare |
| TNBC | triple-negative breast cancer |
| BN | bifunctional theranostic nanoprobe |
| SNNB | sentinel node navigation biopsy |
| MTD | maximum tolerated dose |
| CLIPT | continuous low-irradiance PDT |
| Bcl-2 | B-cell lymphoma 2 |
| DFFA | DNA fragmentation factor alpha |
| CASP2 | caspase 2 |